ストックスクリーナーアプリを入手
2.3005
9.09%
0.2105
前日終値:
$2.09
開ける：
$2.15
24時間の取引高:
6,519
Relative Volume:
0.07
時価総額：
$92.53M
収益：
$18.11M
当期純損益:
$-18.95M
株価収益率:
-2.6672
EPS:
-0.8625
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.72%
1か月 パフォーマンス:
-15.56%
6か月 パフォーマンス:
-11.97%
1年 パフォーマンス:
+68.89%
1日の値動き範囲:
$2.15
$2.3458
1週間の範囲:
$2.01
$2.4438
52週間の値動き範囲:
$1.34
$4.38
Adagene Inc Adr Stock (ADAG) Company Profile
ADAG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ADAG | 2.30 | 92.53M | 18.11M | -18.95M | 0 | -0.8625 |
| VRTX | 449.69 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.75 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.89 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.52 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-06-25 | 開始されました | China Renaissance | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
Adagene Inc Adr (ADAG) 最新ニュース
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Anheuser-Busch InBev S.A. ADR falls Tuesday, underperforms market - MSN
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Adagene's ADG126 Shows Breakthrough Results in Cancer Treatment, Outperforms Ipilimumab | ADAG Stock News - StockTitan
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Anheuser-Busch InBev S.A. ADR rises Thursday, outperforms market - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance
Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart
Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow
Adagene Announces Updates to its Board of Directors - Quantisnow
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Quantisnow
Adagene Inc Adr (ADAG) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):